RxDoctor Payments Data

Kimberly Hardin

Family · New Albany, MSNPI 1841392784

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 734 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 7.0% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,242in general payments, 2019–2025

Across 734 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$995
  • AstraZeneca$844
  • Bristol Myers Squibb$818
  • E.r. Squibb & Sons, L.L.C.$793
  • Merck$744
  • Eisai Inc.$730
  • plus $9K from 51 others

What the payments were for

  • Food & beverage$13,24293%
  • Education$9997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,242 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$29,069
Medicare patients
239
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib12$209,980
IressaGefitinib12$92,943
Exemestane19$980
Letrozole75$929
Potassium Chloride67$805
Acyclovir44$428
Gabapentin25$415
Tamoxifen Citrate32$405
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$334
Hydroxyurea16$309
Allopurinol26$272
Dexamethasone11$156
Ondansetron OdtOndansetron15$132
Warfarin Sodium22$123
Celecoxib11$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$57$209,98012 claims
AstraZenecaIressa$844$92,94312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in New Albany

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →